Concord Biotech Limited has filed its Business Responsibility and Sustainability Report for the financial year 2025-26, disclosing its performance on environmental, social, and governance (ESG) parameters. The report, which forms part of the 41st Annual Report, has undergone reasonable assurance by M/s. Ramanlal G. Shah & Co., Chartered Accountants, validating the accuracy of the identified sustainability information including greenhouse gas emissions, water footprint, and employee safety metrics.

The company reported a total workforce of 2,899 individuals, comprising 1,624 employees and 1,275 workers. Women constitute approximately 7.02% of the permanent employee workforce and 2.20% of the permanent worker workforce. The median remuneration for employees other than the Board of Directors and Key Managerial Personnel was ₹600,000 per annum for males and ₹328,980 per annum for females.

Concord Biotech operates four manufacturing plants nationally and serves over 70 countries, with exports contributing 46.56% to the total turnover. The company’s primary business activities include the research, development, manufacturing, and sale of active pharmaceutical ingredients (APIs), which accounted for 78.6% of the turnover, and finished formulations, which accounted for 21.4%.

Environmental Performance

The company reported total water withdrawal of 3,88,780.1 kilolitres for FY26, with groundwater being the primary source. Water intensity per rupee of turnover stood at 0.0000368. Concord Biotech has implemented Zero Liquid Discharge (ZLD) mechanisms across all facilities, utilizing Effluent Treatment Plants (ETPs), Reverse Osmosis (RO), and Multiple Effect Evaporators (MEE) to treat and recycle wastewater.

Air emissions data indicated a rise in nitrogen oxides (NOx) to 1,65,135.23 Kg/Year from 1,42,472.60 Kg/Year in the previous year, and sulfur oxides (SOx) to 2,51,427.15 Kg/Year from 2,02,026.61 Kg/Year. The company has initiated several projects to reduce greenhouse gas emissions, including switching to natural gas for steam generation and installing energy-efficient equipment.

Governance and Assurance

The report highlights that the company received zero complaints regarding sexual harassment, forced labour, or other human rights issues during the financial year. Additionally, there were no reported instances of data breaches, product recalls, or fines imposed by regulatory bodies for non-compliance.

M/s. Ramanlal G. Shah & Co. provided reasonable assurance on the identified sustainability information, confirming that the data was prepared in all material respects in accordance with the criteria, including the Guidance Note for BRSR format. The assurance engagement excluded operations outside the defined scope and forward-looking statements.

Key Financial and Operational Metrics

Concord Biotech has successfully completed regulatory inspections at its Unit-II Formulation Facility, conducted by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda. The inspection took place from June 18, 2026 to June 24, 2026. This milestone strengthens the company's global manufacturing footprint and regulatory standing in key African markets.

Regulatory Inspection Details

The successful completion of these inspections underscores Concord Biotech's adherence to international pharmaceutical manufacturing and quality standards. The key details of the regulatory assessments are outlined below:

Significance of the Development

The clearance from both the Kenyan and Ugandan drug regulatory authorities reflects the company's commitment to maintaining robust quality and compliance frameworks at its formulation manufacturing unit. Approvals from the PPB and the NDA are essential for market access and product distribution in Kenya and Uganda, respectively, and are recognized as credible regulatory benchmarks within the African pharmaceutical landscape.

This successful inspection outcome at the Unit-II Formulation Facility positions Concord Biotech to strengthen its regulatory standing across key African markets, reinforcing its presence in the region's pharmaceutical sector.